This international phase III trial ( Investigating Torisel As Second-Line Therapy -LSB- INTORSECT -RSB- ) compared the efficacy of temsirolimus ( mammalian target of rapamycin inhibitor ) and sorafenib ( vascular endothelial growth factor receptor -LSB- VEGFR -RSB- tyrosine kinase inhibitor ) as second-line therapy in patients with metastatic renal cell carcinoma ( mRCC ) after disease progression on sunitinib .